BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

CAPS Rating: 1 out of 5

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

Recs

2
Player Avatar acecannon (53.15) Submitted: 4/18/2007 3:03:23 PM : Underperform Start Price: $9.58 BCRX Score: +11.51

It's not a matter of if, but when, the stock goes to 0. My pick is for an outbreak of 0 in Asia first, followed by Canada, then lastly America.

Featured Broker Partners


Advertisement